Alvimopan for postoperative ileus

American Journal of Health-System Pharmacy

Volumn 66, Issue 14, 2009, Pages 1267-1277

  Bream Rouwenhorst, Heather R ^a,b   Cantrell, Matthew A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alvimopan; Dosage; Drug administration; Drug interactions; Hospitals; Ileus; Mechanism of action; Opiate antagonists; Pharmacoeconomics; Pharmacokinetics; Postoperative complications; Toxicity

Indexed keywords

ADL 080011; ALVIMOPAN; ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; DRUG METABOLITE; ERYTHROMYCIN; METHADONE; METOCLOPRAMIDE; MORPHINE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG; WATER;

ABDOMINAL DISTENSION; ANALGESIA; CARDIOVASCULAR DISEASE; CHILD CARE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYSTERECTOMY; ILEUS; KIDNEY FAILURE; LACTATION; LIVER FAILURE; MUSCLE CRAMP; NAUSEA; NEOPLASM; NONHUMAN; OPIATE ADDICTION; PAIN; POSTOPERATIVE COMPLICATION; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 67650983225     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080445     Document Type: Review

References (47)

1. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000; 87: 1480-1493
2. Maron DJ, Fry RD. New therapies in the treatment of postoperative ileus after gastrointestinal surgery. Am J Ther. 2008; 15:59-65.
3. Leslie JB. Alvimopan for the management of postoperative ileus. Ann Pharmacother. 2005; 39:1502-1510
4. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001; 182(suppl 5A): 3S-10S.
5. Kalff JC, Schraut WH, Simmons RL et al. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg. 1998; 228:652-663 (Pubitemid 128719595)
6. Kalff JC, Schraut WH, Billiar TR et al. Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology. 2000; 118:316-327 (Pubitemid 30067505)
7. Marshall FN, Pittinger CB, Long JP. Effects of halothane on gastrointestinal motility. Anesthesiology. 1961; 22:363-366
8. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182(suppl 5A):11S-18S. (Pubitemid 34072942)
9. Kehlet H. Postoperative ileus. Gut. 2000; 47(suppl 4):iv85-86.
10. Prasad M, Matthews JB. Deflating postoperative ileus. Gastroenterology. 1999; 117:489-492
11. Tollesson PO, Cassuto J, Rimbäck G. Patterns of propulsive motility in the human colon after abdominal operations. Eur J Surg. 1992; 158:233-236
12. Sarawate CA, Lin SL, Walton SM et al. Economic burden of postoperative ileus (POI) in abdominal surgical procedures. Gastroenterology. 2003; 124:A828. Abstract.
13. Steinbrook RA. An opioid antagonist for postoperative ileus. N Engl J Med. 2001; 345:988-989
14. Bungard TJ, Kale-Pradhan PB. Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature. Pharmacotherapy. 1999; 19:416-423 (Pubitemid 29160155)
15. Goodman AJ, Le Bourdonnec B, Dolle RE. Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007; 2:1552-1570
16. Sternini C, Patierno S, Selmer IS et al. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004; 16 (suppl 2):3-16.
17. DeHaven-Hudkins DL, DeHaven RN, Little PJ et al. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther. 2008; 117:162-187
18. Schmidt WK. Alvimopan (ADL-8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001; 182(suppl 5A):27S-38S.
19. Zimmerman DM, Gidda JS, Cantrell BE et al. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994; 37:2262-2265
20. Zimmerman DM, Nickander R, Horng JS et al. New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series. Nature. 1978; 275:332-334 (Pubitemid 9014799)
21. Zimmerman DM, Gidda JS, Cantrell BE et al. LY246736 dihydrate: μ-opioid receptor antagonist. Drugs Future. 1994; 19:1078-1083
22. Azodo IA, Ehrenpreis ED. Alvimopan (Adolor/GlaxoSmithKline). Curr Opin Investig Drugs. 2002; 3:1496-1501
23. Beattie DT, Cheruvu M, Mai N et al. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-001I and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375:205-220 (Pubitemid 46525447)
24. Le Bourdonnec BL, Barker WM, Belanger S et al. Novel trans-3,4-dimethyl- 4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008; 18:2006-2012
25. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil. 2005; 17:157-65. (Pubitemid 40476675)
26. Entereg (alvimopan) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2008 May.
27. Foss JF, Fisher DM, Schmith VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther. 2008; 83:770-776
28. Senagore AJ, Bauer JJ, Du W et al. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use. Surgery. 2007; 142:478-486 (Pubitemid 47575582)
29. Liu SS, Hodgson PS, Carpenter RL et al. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001; 69:66-71.
30. Taguchi A, Sharma N, Saleem RM et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001; 345:935-940 (Pubitemid 34940808)
31. Wolff BG, Michelassi F, Gerkin TM et al. Alvimopan, a novel, peripherally acting μ opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004; 240:728-734
32. Delaney CP, Weese JL, Hyman NH et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005; 48:1114-1125
33. Viscusi ER, Goldstein S, Witkowski T et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006; 20:64-70. (Pubitemid 43097035)
34. Ludwig K, Enker WE, Delaney CP et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008; 143:1098-1105
35. Büchler MW, Seiler CM, Monson JR et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008; 28:312-325
36. Wolff BG, Weese JL, Ludwig KA et al. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg. 2007; 204:609-616
37. Büchler MW, Monson JR, Flamant Y et al. Recovery of gastrointestinal function following bowel resection: results of a European double-blind, randomized, placebo-controlled study and comparison with US experience. Paper presented at American Society of Colon and Rectal Surgeons. Seattle, WA; 2006 Jun 3. Abstract.
38. Wolff BG, Viscusi ER, Delaney CP et al. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase III North American clinical trials. J Am Coll Surg. 2007; 205:43-51.
39. Herzog TJ, Coleman RL, Guerrieri JP et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006; 195:445-453
40. Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized controlled trial. J Pain. 2005; 6:184-192
41. GlaxoSmithKline. FDA issues approvable letter for Entereg for POI. www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=923 (accessed 2008 Jun 26).
42. GlaxoSmithKline and Adolor Corporation. GSK and Adolor announce preliminary results from phase 3 safety study of alvimopan (Entereg/Entrareg). http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irolnewsArticle&t= Regular&id=982960& (accessed 2008 Jun 26).
43. Mortensen E. Entereg (aIvimopan) OBD study GSK014 safety findings. www.fda.gov/ohrms/dockets/ac/08/slides/2008-4336s1-04-Adolor-Mortensen.pdf (accessed 2008 Oct 9).
44. Woods MS. Postoperative ileus: dogma versus data from bench to bedside. Perspect Colon Rectal Surg. 2000; 12:57-76.
45. Delaney CP. Clinical perspective on postoperative ileus and the effect of opiates. Neurogastroenterol Motil. 2004; 16(suppl 2):61-66
46. Salvador CG, Sikirica M, Evans A et al. Clinical and economic outcomes of patients with prolonged postoperative ileus undergoing hysterectomy and hemicolectomy at an academic medical institution. Paper presented at ASHP Midyear Clinical Meeting. Orlando, FL; 2004 Dec 7.
47. Bell TJ, Posten SA, Kraft MD et al. Economic analysis of alvimopan in North American phase III efficacy trials. Am J Health-Syst Pharm. 2009; 66: in press.